Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 recep...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMJ Publishing Group 2023-06-01
Серія:	Journal for ImmunoTherapy of Cancer
Онлайн доступ:	https://jitc.bmj.com/content/11/6/e006814.full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Схожі ресурси